POMDOCTOR LTD - A
POMNASDAQTrading Snapshot
- Day Range
- $1.72 β $1.72
- 52-Week Range
- $0.43 β $102.42
- Volume (shares)
- 316
- Avg Volume (shares)
- β
- Shares Outstanding
- 8.6M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $400M
- Last Q Revenue
- $27M
- P/E Ratio
- -0.2
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-37.37
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +106.8%
POMDOCTOR LTD - A
POMAbout POMDOCTOR LTD - A
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

POMDOCTOR LIMITED Highlights Real-World Data as a Strategic Foundation for AI-Enabled Healthcare Solutions
Company emphasizes the expanding applications of real-world data in medical research, clinical decision-making, healthcare payment and personalized treatment GUANGZHOU, China, Nov. 11, 2026 /PRNewswire/ -- POMDOCTOR LIMI

POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
GUANGZHOU, China, Nov. 6, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare c

POMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare Payment
Building a Four-Tier Revenue Structure Across B2C Services, AI-Enabled Chronic Disease Management, B2B Healthcare Services, and Pharmaceutical RWS/RWD GUANGZHOU, China, Nov. 4, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Po

POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements
GUANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare c

POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq
GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solution

POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare
GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solution